---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-067446"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:55:16.272745+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics reports Phase 1 ELiPSE-1 data: 30% CRR, 40% ORR in R/R NHL; no DLTs

## Summary
- As of March 27, 2024, 12 patients evaluable for safety; no DLTs or GvHD observed; most cycles outpatient.
- Across all dose levels (10 evaluable), 30% complete response rate and 40% objective response rate.
- At Schedule A dose levels 300M and 1B cells, 40% CRR and 60% ORR in 5 heavily pre-treated patients.
- Novel cfDNA assay suggests CNTY-101 persists in tissues; AUC trends with dose.
- Dose escalation continues at DL3B (3 weekly infusions of 1B cells) and DL4A (single 3B cells).

## SEC filing metadata
- accession: 0001104659-24-067446
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924067446/0001104659-24-067446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924067446/tm2416244d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-067446
- JSON: https://secwatch.observer/filing/0001104659-24-067446.json
- Plain text: https://secwatch.observer/filing/0001104659-24-067446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.